Gracey Craig sold $26K of OMDA

Gracey Craig (Chief Accounting Officer) sold 1,042 shares of Omada Health, Inc. (OMDA) at $25.00 on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gracey Craig
Published Aug 12, 2026, 8:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMDA
Neutral
high confidence
Mentioned
$OMDA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMDANeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and that it was executed under a pre-arranged 10b5-1 plan; there is no accompanying guidance, contract, or regulatory development.

02

Market read

Traders may monitor insider activity, but this particular disclosure is unlikely to change the fundamental outlook absent other catalysts.

03

What to watch

The filing does not state motivations, tax considerations, or whether other insiders sold/bought around the same time; traders may need broader insider-flow context.

Relevance 2/10Novelty 3/10Timing: Filed after-hours on 2026-08-12, covering a sale executed 2026-08-10.

Background

The article is an SEC Form 4 insider transaction disclosure for Omada Health, Inc.

Company-level read

Ticker impact

$OMDANeutralHigh confidence
Context

Omada Health CFO Gracey Craig sold 1,042 shares at $25.00 on 2026-08-10 under a pre-arranged 10b5-1 plan, per Form 4.

Expected impact

Low likelihood of a sustained price move driven by this filing alone; any reaction would be sentiment-driven and likely short-lived.

Evidence & confidence

The disclosure is an open-market sale by an officer, explicitly tied to a pre-arranged 10b5-1 plan, and the article provides no new company-specific operational or financial catalyst.

Market effects

No clear sector read-through from a single officer 10b5-1 sale without accompanying company news.

None indicated.

None indicated.

Counterpoint

Insider sales can still coincide with private information, but the 10b5-1 designation materially reduces that inference.

Key entities

  • Omada Health, Inc.

    Subject of the Form 4 insider transaction disclosure (OMDA).

  • Gracey Craig

    Chief Accounting Officer who sold 1,042 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMDAHigh

Omada Health Earnings Call Signals Strong Growth Ahead

Omada Health (OMDA) reported Q3 revenue of $91M, up 34% YoY, with GAAP net income of $7M vs. a loss last year. Adjusted EBITDA rose to $12M. Management raised 2026 revenue guidance to $344M-$346M and adjusted EBITDA to $32M-$34M, citing strong demand for diabetes and hypertension programs. The company expects Q4 seasonality and GLP-1 coverage uncertainty.

$OMDAMed

What Omada Health (OMDA) Said on Its Q3 Earnings Call

Omada Health (OMDA) expects Q4 revenue to decline due to seasonal factors, with adjusted EBITDA also moderating. The company ended Q3 with $243M in cash and no debt. CEO Sean Duffy will transition to executive chair in 2027, with Shao taking over as CEO. Omada's GLP-1 Care Track showed a 6% average weight loss at 12 weeks, according to peer-reviewed research.

$OMDAMedAI 8/10

Omada Health Inc (OMDA) (Q3 2026) Earnings Call Highlights: Record Revenue, Membership

Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.